Document Detail


Nephrotic syndrome as a complication of anti-TNFalpha in a patient with rheumatoid arthritis.
MedLine Citation:
PMID:  12852723     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We describe a patient with rheumatoid arthritis (RA) who developed a nephrotic syndrome during treatment with a fully human recombinant monoclonal antibody against TNFalpha (adalimumab, Humira, Abbott). The proteinuria disappeared spontaneously after cessation of anti-TNFalpha treatment and relapsed after rechallenge, pointing to anti-TNFalpha as the culprit. Although renal biopsy disclosed a membranous glomerulopathy, the clinical picture was more compatible with minimal lesion glomerulopathy. The pathogenesis of this side effect is not clear; several mechanisms could in theory lead to these abnormalities.
Authors:
A A den Broeder; K J M Assmann; P L C M van Riel; J F M Wetzels
Related Documents :
17333003 - Superior sagittal sinus thrombosis and bilateral sixth-nerve palsy in a child with neph...
12453603 - Latent cerebral hypoperfusion in a boy with persistent nephrotic syndrome.
19650413 - Double outlet right ventricle and aortopulmonary window in a patient with cornelia de l...
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  The Netherlands journal of medicine     Volume:  61     ISSN:  0300-2977     ISO Abbreviation:  Neth J Med     Publication Date:  2003 Apr 
Date Detail:
Created Date:  2003-07-10     Completed Date:  2003-07-29     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0356133     Medline TA:  Neth J Med     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  137-41     Citation Subset:  IM    
Affiliation:
Department of Rheumatology, University Medical Centre St Radboud, PO Box 9101, 6500 HB Nijmegen, The Netherlands. alfonsenellen.broeder@hccnet.nl
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antibodies, Monoclonal / adverse effects*,  therapeutic use
Arthritis, Rheumatoid / drug therapy*
Humans
Male
Middle Aged
Nephrotic Syndrome / etiology*
Tumor Necrosis Factor-alpha / antagonists & inhibitors*,  immunology
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Tumor Necrosis Factor-alpha; 0/adalimumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Improvement of glycaemic control in type 2 diabetes: favourable changes in blood pressure, total cho...
Next Document:  Adrenal carcinoma causing secondary amyloidosis: report of the first case in the literature.